Date: 2014-12-29
Type of information: Collaboration agreement
Compound:
Company: Nestlé (Switzerland) EpiGen Consortium
Therapeutic area: Nutrition - Metabolic diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On December 29, 2014, Nestlé has announced it will contribute CHF 22 million to a six-year research partnership with an international alliance of researchers at institutions in Southampton, Auckland and Singapore, who make up the EpiGen Consortium. The jointly-funded public-private partnership will be one of the largest of its kind. Nestlé has been collaborating with the Consortium since 2011, studying how the diet and lifestyles of pregnant women influence the activity of their baby’s genes and how these subtle epigenetic changes impact the future healthy growth and development of their children.The collaboration aims to improve nutrition and reduce risk factors of pregnancy-related conditions such as gestational diabetes, a growing problem affecting about 20% of pregnancies in the South-East Asia region. Gestational diabetes is known to negatively impact the growth and development of children as well as the mother’s future health. EpiGen is a global consortium of leading researchers based in three countries (Auckland UniServices Limited, University of Southampton, Medical Research Council Lifecourse Epidemiology Unit - University of Southampton, Singapore Institute for Clinical Sciences of the Agency for Science, Technology and Research (A*STAR), and National University of Singapore). EpiGen strives to advance understanding of the developmental and environmental processes that influence health through the lifecourse.
Financial terms:
Latest news:
